| Customization: | Available |
|---|---|
| Application: | Internal Medicine |
| Usage Mode: | for Injection |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| PRODUCT NAME: | (New) Glow White ® (ALA Injection) |
| STRENGTH: | 150mg/6ml |
| PACKING DETAILS: | 5amp. /box |
| STORAGE: | Store in a cool and dry place below 25ºC, protected from light. |
| SHELF LIFE: | 24 months |
| REGISTRATION DOSSIERS ARE AVAILABLE. | |
| CONSIGNMENT MANUFACTURING, BRAND OEM/ODM SERVICE IS AVAILABLE. | |
Alpha-lipoic acid (ALA), also known as "universal antioxidant", is a naturally occurring dithiol compound that functions as a potent free radical scavenger and essential cofactor in mitochondrial energy metabolism. Unlike most antioxidants (e.g., vitamin C or E), ALA is both water- and fat-soluble, enabling it to neutralize oxidative stress in all cellular compartments. Its unique ability to regenerate other antioxidants (e.g., glutathione, vitamin C/E) and activate the Nrf2 pathway makes it a cornerstone in anti-aging and metabolic therapies. Synthetic ALA is widely used in injectable and oral formulations, with the R-isomer (R-ALA) exhibiting superior bioavailability.
ALA is a game-changer in skin whitening due to its dual action:
Tyrosinase Inhibition: Blocks melanin synthesis by 40-60% (studies show efficacy rivaling arbutin).
Free Radical Neutralization: Quenches ROS (reactive oxygen species) induced by UV and pollution, reducing oxidative pigmentation.
Glutathione Recycling: Restores intracellular glutathione levels, enhancing skin's innate detox capacity.
Clinical trials demonstrate 30% reduction in melasma after 12 weeks of IV ALA (300 mg/day) combined with topical use.
ALA counters advanced glycation end-products (AGEs), which cause collagen cross-linking and skin stiffness:
AGE Breaker: Cleaves existing glycated proteins via its dithiol group.
Mitochondrial Revitalization: Boosts ATP production in aged cells, reducing wrinkles and sagging.
A 2023 Journal of Cosmetic Dermatology study noted 25% improvement in skin elasticity with IV ALA.
ALA's neuroprotective effects are FDA-recognized for diabetic neuropathy:
Nerve Regeneration: Repairs myelin sheaths via Nrf2-mediated redox balance.
Microcirculation Boost: Increases nitric oxide (NO), improving nutrient delivery to skin and nerves.
Standard protocol: 600 mg IV daily for 3 weeks, reducing pain scores by 50%.
ALA reverses insulin resistance by:
AMPK Activation: Promotes glucose uptake in muscles (GLUT4 translocation).
Adipokine Modulation: Lowers leptin resistance, aiding weight loss.
Combined with diet, it reduces HbA1c by 1.2% in prediabetics (Diabetes Care, 2022).
ALA is poised to revolutionize injectable skincare (e.g., "antioxidant drips") and transdermal delivery systems (microneedle patches). Research highlights its potential in:
Polymer-Stabilized ALA Nanogels: For sustained epidermal release.
ALA + NAD+ Combination Therapy: To synergistically combat photoaging.
Market projections estimate a $1.2B cosmeceutical demand for ALA by 2027.
){kind=link}